The Superficial Musculoaponeurotic System (SMAS) is the fibromuscular layer that connects the facial muscles to the overlying dermis, functioning as the structural scaffold of the mid- and lower face. SMAS integrity refers to the tensile strength, cohesion, and vertical positioning of this anatomical layer.

As the SMAS loses integrity with age — through a process of fibrous thinning, gravitational descent, and ligamentous attenuation — the overlying soft tissue structures migrate inferiorly, producing jowl formation, nasolabial deepening, and effacement of the mandibular border. SMAS integrity is assessed as part of every comprehensive facial evaluation at this practice.

Bony resorption refers to the progressive reduction in craniofacial skeletal volume that occurs throughout adult life. The facial skeleton is not a static structure — the maxilla, zygoma, mandible, and orbital rims undergo measurable volumetric loss beginning in the third decade and accelerating after menopause in women.

The clinical consequence is a reduction in the osseous foundation upon which soft tissue structures rest. As the skeletal scaffold recedes, overlying skin and fat compartments lose their anatomical support, producing the characteristic signs of facial aging that are not attributable to soft tissue changes alone. Correcting soft tissue without accounting for underlying bony resorption produces results that are volumetrically incongruent with the patient’s skeletal architecture.

Calcitonin Gene-Related Peptide (CGRP) is a neuropeptide released from trigeminal nerve terminals that plays a central role in migraine pathophysiology. During a migraine attack, CGRP is released in elevated concentrations from both peripheral trigeminal afferents and central neurons, producing vasodilation, neurogenic inflammation, and the sensitization of pain pathways that characterize the full migraine episode.

The CGRP pathway has become one of the most significant pharmacological targets in modern migraine medicine. CGRP receptor antagonists (gepants) block the peptide’s action at the receptor level; anti-CGRP monoclonal antibodies target the peptide or its receptor directly, providing monthly or quarterly preventive coverage with a mechanism of action specific to migraine biology.

Regenerative biostimulation refers to a class of aesthetic interventions that do not simply add volume or block neuromuscular activity, but instead activate the body’s intrinsic cellular mechanisms of collagen synthesis, dermal matrix renewal, and structural tissue regeneration. The result is improvement in skin quality, firmness, and structural integrity that develops progressively over months rather than immediately.

Primary biostimulatory agents include Poly-L-lactic acid (PLLA, marketed as Sculptra), calcium hydroxylapatite (CaHA, marketed as Radiesse), and polynucleotide complexes. Each activates fibroblast activity through distinct mechanisms, producing neocollagenesis — the synthesis of new collagen within the treated dermis and subdermis — rather than mechanical displacement of existing tissue structures.

A documented clinical indication is a formally recorded, evidence-based rationale that justifies a specific medical or aesthetic intervention for a specific patient at a specific point in their clinical course. At Monti Institute, no procedure — neurological or aesthetic — is performed without one.

In neurological practice, a documented clinical indication for Botox for chronic migraine, for example, requires a confirmed diagnosis of chronic migraine (≥15 headache days per month, ≥8 of which meet migraine criteria), documented inadequacy of prior preventive treatments, and physician-recorded clinical reasoning supporting this intervention for this patient.

In aesthetic practice, it means that the choice of treatment, product, volume, and injection site is recorded in the clinical record with a specific anatomical rationale — not simply selected from a standard menu. This standard distinguishes physician-led aesthetic care from high-volume aesthetic practice.